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Background
In the past two decades, subanaesthetic doses of ketamine have
been demonstrated to have rapid and sustained antidepressant
effects, and accumulating research has demonstrated keta-
mine’s therapeutic effects for a range of psychiatric conditions.
Aims
In light of these findings surrounding ketamine’s psychothera-
peutic potential, we systematically review the extant evidence
on ketamine’s effects in treating mental health disorders.
Method
The systematic review protocol was registered in PROSPERO
(identifier CRD42019130636). Human studies investigating the
therapeutic effects of ketamine in the treatment of mental health
disorders were included. Because of the extensive research in
depression, bipolar disorder and suicidal ideation, only system-
atic reviews and meta-analyses were included. We searched
Medline and PsycINFO on 21 October 2020. Risk-of-bias analysis
was assessed with the Cochrane Risk of Bias tools and A
Measurement Tool to Assess Systematic Reviews (AMSTAR)
Checklist.
Results
We included 83 published reports in the final review: 33 sys-
tematic reviews, 29 randomised controlled trials, two
randomised trials without placebo, three non-randomised trials
with controls, six open-label trials and ten retrospective reviews.
The results were presented via narrative synthesis.
Conclusions
Systematic reviews and meta-analyses provide support for
robust, rapid and transient antidepressant and anti-suicidal
effects of ketamine. Evidence for other indications is less robust,
but suggests similarly positive and short-lived effects. The con-
clusions should be interpreted with caution because of the high
risk of bias of included studies. Optimal dosing, modes of
administration and the most effective forms of adjunctive psy-
chotherapeutic support should be examined further.
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Background
Ketamine is an N-methyl-d-Aspartate receptor agonist with well-
established safety and efficacy as an analgesic and anaesthetic.
Since ketamine was developed in 1964, largely as a replacement
for phencyclidine, it has been used primarily in veterinary and
paediatric anaesthesia, but interest in recent years has burgeoned
in psychiatry after reports of its rapid-acting antidepressant
effects.1 The potential for ketamine to be used in the treatment of
psychiatric disorders was first noted in the 1970s,2 and has been
the focus of formal investigation since the 1990s, with investigative
and off-label use in the context of mental health increasing across
North America and Europe since that time. The first approval by
the USA Food and Drug Administration (FDA) of a ketamine-
derived therapy for mental health came in 2019 for intranasal eske-
tamine (the S-enantiomer of ketamine) as augmentation therapy for
treatment-resistant depression, which has increased clinical and
public interest internationally.
The past two decades have seen the development of ketamine
for treatment of a broad range of mental health conditions
beyond depression. Although a number of meta-analyses and sys-
tematic reviews have evaluated the use of ketamine in depression,3,4
there is less synthesised literature across other psychiatric uses. The
current review integrates parallel reviews of the nascent research on
ketamine as a treatment for mental health conditions and related
research germane to the therapeutic potential of ketamine for
mental health more broadly. This work is timely as off-label pre-
scribing of ketamine for a large number of psychiatric disorders
other than depression continues,5 but there have been no compre-
hensive syntheses of the state of the evidence so far.
Route of administration, dose and therapeutic support
Route of administration is a key consideration in the use of keta-
mine for disorders such as depression, in which repeated or semi-
regular dosing may be indicated.3 Intravenous is most widely used
route of administration in clinical settings because of its superior
bioavailability and control of dose. However, other modes of admin-
istration, such as oral, intramuscular, sublingual and intranasal,
which require less clinical resources, have clear practical advantages
for repeated dosing and patient comfort.3,6–9
Psychoactive and therapeutic effects of ketamine have also been
reported to vary substantially by dose and route of administra-
tion.10,11 For example, the ketamine-assisted psychotherapy (KAP)
model proposes distinct applications according to dose and mode,
with lower-dose sublingual administration recommended for ses-
sions that involve more active therapist–patient communication,
and higher-dose intramuscular administration recommended for ses-
sions that adhere more closely to current models of psychedelic psy-
chotherapy with an inward focus, eye coverings and music.12
However, studies that have compared modes of administration
have generally not reported meaningful differences in efficacy.13,14* Joint first authors.
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Research on the ketamine dose–response relationship in the
context of mental health is equivocal.15 Early studies to treat addic-
tion used higher doses of 2–3.0 mg/kg administered via intramuscu-
lar injection,16–19 whereas more recent studies typically use 0.4 mg/
kg or 0.5 mg/kg administered intravenously, infused over 40–60
min.20–22 Ketamine effects in depression generally last from a few
days to 2 weeks,15 so repeated dosing is usually necessary to
extend recovery. For example, the FDA-approved dosing model
for esketamine includes an induction phase of twice weekly
dosing, tapering down to a maintenance phase of weekly and later
biweekly dosing, with no maximum period indicated.23 In general,
further empirical work is required to confidently assert an optimal
model of ketamine administration.
Psychoactive drugs have been proposed to work synergistically
with psychological therapies,24 and support for preparation and inte-
gration are recognised as essential components of psychedelic-assisted
psychotherapy.25 However, distinct psychotherapeutic support has
not typically been emphasised in current psychiatric use of ketamine.
The FDA-approved model of esketamine for treatment-resistant
depression does not explicitly demand therapist engagement in prep-
aration or integration of experiences. The relative lack of emphasis on
adjunctive psychotherapy contrasts with the early work in ketamine-
assisted psychotherapy by Salvador Roquet and his colleagues in
Mexico in the 1970s26,27 which was embedded in a psychodynamically
informed group therapy. Subsequent work in addiction also adminis-
tered ketamine in the context of psychodynamic group therapy,17 and
follow-up assessments of these groups suggested this intensive therapy
programme was key to the effectiveness of ketamine in the treatment
of alcohol use disorder.28 More recently, adjunct cognitive–behav-
ioural therapy following ketamine infusions was found to prolong
the therapeutic effects of ketamine for depression.29 The increasingly
prominent KAP model also strongly emphasises the role of both
therapeutic support and set and setting in accentuating and extending
the longevity of ketamine effects.12
Approaches to ketamine therapy that involve active therapeutic
support, such as KAP, leverage the subjective psychoactive effects of
ketamine administration to maximise therapeutic benefit.12 Indeed,
although the role of the acute psychoactive effects of ketamine
remains a subject of debate, theory and research suggests that
these effects may be important, and perhaps even central. For
example, a ketamine-assisted psychotherapy session using a single
psychedelic dose of ketamine produced higher rates of abstinence
from heroin users than did a low sub-psychedelic dose.18 Further,
an analysis of data from several studies of in-patient use of ketamine
for the treatment of depression found that dissociative effects during
the infusion were correlated with the antidepressant response.30
Another study in cocaine users identified a strong mediating
effect of mystical experiences on ketamine-related reductions in
cocaine use and craving, leading the authors to call for approaches
to ketamine therapy that explicitly evoke and capitalise on the salu-
tary effects of mystical experiences.31 However, a broad systematic
review of the associations between psychoactive effects and keta-
mine treatment outcomes was inconclusive.32
The current review
Although a number of meta-analyses and systematic reviews have
evaluated the use of ketamine in depression,3,4 little work thus far
has synthesised literature across other psychiatric uses of ketamine.
The current review aims to evaluate the therapeutic benefits of keta-
mine treatment on psychiatric disorders, including depression,
bipolar disorder, social and generalised anxiety, obsessive–compul-
sive disorders, post-traumatic stress disorders, substance use disor-
ders and eating disorders. The review will also assess whether
ketamine anaesthesia for electroconvulsive therapy (ECT) is
effective for the treatment of these psychiatric disorders, and any
adverse effects associated with ketamine treatment.
Method
Methods of the systematic review were specified in advance and
documented in a protocol registered on PROSPERO (identifier:
CRD42019130636). The systematic review was conducted and
reported in line with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) 2020 guidelines33.
Eligibility criteria
We included any human studies investigating the clinical effect of
ketamine, S(+)-ketamine (esketamine) or R(−)-ketamine (arketa-
mine) in the treatment of mental health disorders. All peer-reviewed
and published reports in English were eligible except for case
studies, letters to editors and comments. Because of the voluminous
research on ketamine’s therapeutic effects in major depressive dis-
order (MDD), bipolar disorder and suicidal ideation, we limited
our review for these topics to systematic reviews and meta-analyses.
We excluded studies with a primary focus on (a) modelling schizo-
phrenia and psychosis symptoms, (b) solely the mechanisms of
action or predictors of treatment response, (c) ketamine metabolites
only (i.e. hydroxyketamine, norketamine, dehydronorketamine and
hydroxynorketamine), (d) the use of ketamine for treatment of
general health conditions, (e) the use of ketamine as an analgesic
or anaesthetic agent and (f) interventions for the treatment of prob-
lematic ketamine use.
Search strategy and information sources
Literature search strategies were developed by using medical subject
headings (MeSH) and text words related to ketamine and mental
health disorders (see Supplementary Materials available at https://
doi.org/10.1192/bjo.2021.1061 for the full search strategy). We
searched Medline (Ovid Interface, 1946 onward) and PsycINFO
(Ovid Interface, 1806 onward). All searches were completed on 21
October 2020. The searches were limited to English language and
human study participants, and no date limits were imposed on
the search. To supplement identification of relevant articles, we
scanned reference lists of included studies or relevant reviews iden-
tified through the search. Before the start of the systematic review,
we also searched PROSPERO for any ongoing or recently completed
systematic reviews in the field.
Study selection
Four independent reviewers screened the titles and abstracts
against the inclusion and exclusion criteria. Before independent
screening, the reviewers screened titles and abstracts of 100
papers each to calculate the interrater reliability. The intraclass
coefficient was 0.98. During the full-text screening stage, reviewers
were trained in using study eligibility forms to ensure consistency.
Discrepant ratings for inclusion criteria were resolved by
consensus.
Data extraction
Four independent reviewers extracted data from included reports,
using data extraction forms that were piloted before use; this
involved a separate form for studies reporting on primary data
and another form for systematic reviews and meta-analyses. For
papers reporting data from individual studies, we extracted the fol-
lowing information: trial design and setting, patient characteristics
(demographics, mental health diagnosis, comorbidities), ketamine
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treatment (dosage, frequency, duration), any adjunctive treatment
(psychological or pharmacological), type of control used (placebo,
active comparisons), treatment outcomes (acute and follow-up)
and adverse effects. For systematic reviews and meta-analyses, we
extracted eligibility criteria, characteristics of studies included,
risk-of-bias analysis of included studies, summary measures, syn-
thesis of results, narrative summary and adverse reactions. See
Supplementary material for both of the data extraction forms. We
contacted one author (Professor P. Glue) regarding the overlap of
samples in three of their papers, to avoid double counting.34–36
With Professor Glue’s guidance, we dealt with the overlap of the
samples by stating in our results which of the studies included the
same participants.
Synthesis methods
Results of individual studies included in the synthesis were pre-
sented in a separate table for each psychiatric diagnosis. Meta-ana-
lysis was not deemed appropriate because of the heterogeneity of
dosage, number and methods of ketamine administrations,
patient populations, study designs and outcome measures. The
results were grouped according to patient population (MDD,
bipolar disorder, suicidal ideation, generalised and social anxiety
disorders, post-traumatic stress disorder, obsessive–compulsive dis-
orders, substance use disorders and eating disorders) and by setting
(ketamine in combination with ECT). Additionally, adverse effects
across all included studies were synthesised together.
Risk of bias
We used version 2 of the Cochrane Risk-of-Bias tool to rate the
quality of randomised controlled trials (RCTs).37 For non-rando-
mised studies, we used the Risk of Bias in Non-randomised
Studies-of Interventions.38 The quality of systematic reviews and
meta-analyses were assessed with the A Measurement Tool to
Assess Systematic Reviews 2 (AMSTAR 2) Checklist.39 Four
reviewers (O.M.M., J. R., S. G. and J.K.) were trained in the use of
tools, and risk-of-bias judgements were made independently, with
disagreements resolved among reviewers.
Results
We included 83 published reports in this systematic review (see
Fig. 1 for PRISMA flow diagram), comprising 33 systematic
reviews (of which 17 included meta-analyses), 29 RCTs, two rando-
mised trials with no placebo control, three non-randomised trials
with controls, six open-label trials and ten retrospective reviews.
A list of studies that appeared to meet the inclusion criteria but
were excluded, and reasons for exclusions, are provided in
Supplementary Table 1.
Unipolar depression and MDD
We identified 24 systematic reviews of the antidepressant effect of
ketamine in the treatment of unipolar depression and/or MDD,
12 of which conducted meta-analyses. In general, reviews consist-
ently identified a robust, rapid, and typically short-lived antidepres-
sant effect for ketamine.
All systematic review or meta-analytic articles noted rapid onset
of ketamine’s antidepressant effect among patients with MDD.3,4,6–
9,14,15,40–53 Meta-analyses, which primarily focused on a single intra-
venous infusions, identified lower mean depression severity and
remission in ketamine groups relative to placebo, with onset
between 1 and 24 h post-infusion,6,9,14,40,41,43,45,47,50,52 and typically
persisting for 1–2 weeks.3,8,9,14,41–43,45,47,49,50 Repeated
administrations of ketamine of up to six doses produce a more pro-
nounced antidepressant effect at the 2-week follow-up relative to a
single administration,43,44,50 and prolonged time to
relapse.3,15,44,47,50
Studies on routes of administration other than intravenous
signal an antidepressant effect comparable with that of intravenous
administration.4,9,14,44,46,52 One meta-analysis demonstrated that
adjunctive intranasal ketamine was significantly more effective
than placebo for reducing depressive symptoms, response and
remission from depression.53 A direct comparison of intravenous
versus intramuscular ketamine for depression concluded that the
methods were equivalent in terms of safety and effectiveness.13
With regards to oral ketamine, a systematic review reported that
repeated administration of oral ketamine was well-tolerated and
had medium-to-large effect sizes, with a delay of 2–6 weeks before
the emergence of clinically significant antidepressant effects.54 A
meta-analysis comparing intravenous, intranasal and oral ketamine
administrations was inconclusive because of heterogeneity across
studies, but noted that effects for intravenous ketamine appeared
to peak at 2–6 days, compared with 24 h for intranasal administra-
tion and 7–20 days for oral administration, potentially because of
increasing bioavailability over time.55
Ketamine is effective both in trials restricted to patients with
treatment-resistant depression (i.e. non-response to prior anti-
depressant trials) and trials that included patients who had
responded to prior treatment.6,45 Likewise, ketamine’s effect has
been identified in patients who are currently taking other anti-
depressant medications, as well as those who are drug-free or
have completed a washout period.6,41,46,49
Bipolar disorder
Themajority of research on ketamine treatment for bipolar disorder
has involved adults identified as resistant to prior treatment, and
primarily tested ketamine as an adjunct to other treatments such
as mood stabilisers or ECT.15,56 We identified 17 systematic
reviews of the antidepressant effect of ketamine in the treatment
of bipolar disorder, nine of which included meta-analyses. One
review56 and two meta-analyses57,58 focused exclusively on bipolar
disorder, whereas the remaining 14 also reviewed unipolar
depression.
Similar to unipolar depression, the reviews found a rapid and
short-lived antidepressant effects of ketamine in patients with
bipolar disorder.6,8,9,14,50,56,57 Meta-analyses identified effects
with onset as early as 4 h43 and consistently by 24 h.6,9,14,50,57,58
Findings are less consistent with respect to duration, with some
analyses concluding that effects are limited to 3 days14,57 and
others reporting that effects retain superiority over placebo at 7
days.43,50 Meta-analyses at 14 days did not find an effect of
ketamine.14,43,57,58
Comparisons of effect size in unipolar versus bipolar depression
populations have not yielded consistent results. A meta-analysis
found no difference at 4 h after administration, and two out of
three meta-analyses reported no difference at 24 h after infusion;
in contrast, one meta-analysis found a larger antidepressant effect
for MDD at 24 h.9,43,50 Similarly, equivocal results are seen at 7-
day follow-up: one meta-analysis identified a stronger effect in
bipolar depression43 and one found no difference.50 Notably, the
seven meta-analyses included in the present review rely on data
extracted from two RCTs conducted by the same research
group.59,60 In sum, extant findings do not support a consistent dif-
ference in ketamine effects on depressive episodes in MDD versus
bipolar disorder.
The main concern of ketamine treatment for bipolar disorder is
the risk of inducing mania. Although manic symptoms in patients
Ketamine treatment for mental and health substance use disorders
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with bipolar disorder have been noted to increase immediately fol-
lowing ketamine infusion, these symptoms tend to resolve within 1
or 2 h.6,14,56 In a meta-analysis, it was reported that treatment emer-
gent mania was not observed statistically significantly more fre-
quently in the active intervention group compared with the
placebo.58 However, this meta-analysis is probably underpowered
to detect uncommon adverse effects such as mania.58–60
Likewise, evidence from case studies, open-label trials and retro-
spective chart analyses suggest that non-intravenously (i.e. intra-
muscular, intranasal and oral) administered ketamine is effective
and safe for adults with bipolar disorder.3,12,15,54,56
Suicidal ideation
We identified six systematic reviews of the effects of ketamine on sui-
cidal ideation,61–66 two of which included ameta-analysis of studies62,66
and onewith ameta-analysis of individual participant data.63 The keta-
mine doses ranged from 0.1 to 3 mg/kg, and were most frequently
administered intravenously, although oral suspension, intranasal,
intramuscular and subcutaneous bolus infusions have also been used
in a number of studies.61,62,64–66 Two reviews were limited to trials of
a single dose of ketamine,62,63 and the other reviews included studies
of multiple doses of ketamine, but did not directly compare
doses.61,64–66 Further data comparing the safety and efficacy of single
and repeated doses of ketamine for suicidal ideation is needed.
The one review that examined route of administration found no
differences between a bolus dose (0.2 mg/kg) and an infusion (0.5
mg/kg).62 However, there is limited evidence on intramuscular,
intranasal and oral formulations for use in suicidal ideation.65
Additionally, in one study of intranasal esketamine, no participants
managed to self-administer the ten pumps to receive the full dose,
because of adverse effects; suggesting that the tolerability of intrana-
sal administration may be poor.66,67
All meta-analyses and systematic reviews concluded that keta-
mine treatment was associated with a moderate-to-large decrease
in suicidal ideation (Cohen’s d = 0.51–0.85).61–66 These effects
appeared within the first 4 h of treatment61,62,66 and were main-
tained for an average of 3 days61,66 up to a week,63,65 although
long-term effects are not reported.65 Among participants who
showed remission of suicidal ideation within 24 h of treatment,
the treatment effect persisted for up to 1 week in approximately
85% of participants. Interestingly, ketamine effects remained signifi-
cant after adjusting for change in depression, suggesting that keta-
mine may have anti-suicidal effects independent of antidepressant
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Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 flow diagram for new systematic reviews that
included searches of databases and registers only. Diagram template obtained from PageMJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC,
Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
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effects.63,65 In one meta-analysis, one of the studies included data on
suicide attempts up to 28 days after treatment; no participants had
attempted suicide in either the ketamine or placebo group during
this time period.66 Interestingly, in another review it was reported
that ketamine led to transient improvements in suicidal ideation
in individuals who had been admitted to hospital because of a
suicide attempt or in those with chronic and severe suicidal idea-
tion.65 Although these data were based on case reports, this high
suicide risk population has been excluded from other trials.65
Interactions with ECT
The combined anaesthetic and antidepressant action of ketamine
make it a logical choice for use in ECT, with the hope that it might
exert additive or perhaps synergistic effects.68 We identified 19
studies of patients with MDD, bipolar disorder and treatment-resist-
ant depression, in which ketamine was either used as an anaesthetic
during ECT or for relapse prevention following ECT treatment. All
studies used intravenous administration with doses ranging from
0.5 to 2 mg/kg. Ketamine was superior in reducing depressive symp-
toms in eight of the 18 studies when compared with an active control
such as methohexital, thiopental or propofol.69–82
Themost consistent evidence for effect of ketamine with ECT is in
the treatment of treatment-resistant depression: three double-blind
RCTs, one partially randomised trial, one open-label trial and one
retrospective review have reported positive findings for the impact
of ketamine on the effectiveness of ECT for treatment-resistant
depression, whereas three RCTs reported no differences between keta-
mine and placebo.83,84 In general, these studies reported that, relative
to other anaesthetics, ketamine was associated with earlier improve-
ments in depression, higher remission rate, better overall improve-
ment longer seizure duration, fewer required ECT sessions and less
cognitive impairment (but see also Carspecken et al79).69–71,76,78,82
In contrast to findings demonstrating the benefit of ketamine as
an adjunct to ECT for treatment-resistant depression, results from
MDD and bipolar disorder are less supportive. A double-blind
RCT of 31 in-patients with MDD reported a more rapid antidepres-
sant effect, lower required electrical dose and longer seizure dur-
ation with ketamine anaesthesia during ECT.77 In a larger RCT
with 172 patients, low-dose (0.3 mg/kg) ketamine-assisted ECT
was associated with higher remission rate compared with routine
ECTwith propofol; interestingly, intermittent ketamine administra-
tion (one in every three ECT sessions) resulted in lower rates of psy-
chiatric complications compared with repeated ketamine
administration with each ECT session.85
Nonetheless, results from six other studies suggest no difference
between ECT with ketamine and ECT with control conditions in
reducing depressive symptoms in those with MDD or bipolar dis-
order,73–75,80,81,86 although one study was reported to lack power
because of small sample size.86 Divergent results may be a result
of differences in effectiveness for adjunctive ketamine in ECT, but
may also reflect differences in treatment as the optimal dosage
and frequency remains undetermined. Indeed, studies that reported
no benefit for ketamine generally involved lower doses of 0.3–0.5
mg/kg,73–75 but not always.86
Aside from the use of ketamine as an anaesthetic agent during
ECT, one pilot study aimed to examine the effectiveness of ketamine
for relapse prevention following response to ECT.87 However, out of
26 patients who responded to ECT treatment, only six were willing
to take part, some because of a lack of interest in further treatment
following successful ECT, and none of the participants completed
the full 4-week treatment protocol.87
Social anxiety and generalised anxiety disorder
We identified six studies of ketamine treatment for social anxiety
disorder and/or generalised anxiety disorder (GAD). A retrospect-
ive review of patients receiving multiple sessions of ketamine
assisted therapy (sublingual and/or intramuscular) in a private prac-
tice setting, revealed significant decrease in anxiety following treat-
ment compared with baseline.12 A study of open-label ascending
dose ketamine (0.25, 0.5 and 1 mg/kg intramuscular at 7-day inter-
vals) among 12 patients with treatment refractory social anxiety dis-
order and/or generalised anxiety disorder reported that 1 mg/kg was
associated with the greatest duration of anxiolytic effects for up to 7
days after infusion.34 Following the 0.5 mg/kg or 1 mg/kg doses, 10
out of 12 patients reported a 50% or more reduction in anxiety and/
or fearfulness.34 In a double-blind study, 12 patients with treatment-
resistant generalised anxiety disorder and/or social anxiety disorder
received three ascending doses of ketamine (0.25, 0.5 and 1 mg/kg)
and midazolam (0.01 mg/kg) at 1-week intervals.88 Eight out of the
12 patients experienced at least a 50% reduction in anxiety and/or
fearfulness.88 A subsequent study from the same investigators
reported dose-related decreases in scores on measures of anxiety
and fearfulness.89 These studies34,88,89 established a higher dose of
ketamine (1 mg/kg) as having the greatest and most durable anxio-
lytic effects, although one reported dose-related improvements in
fearfulness, but not anxiety symptoms.88
Participants who responded to ketamine treatment in the previ-
ous two studies34,89 were enrolled in an open-label maintenance
treatment study for 14 weeks (n = 20), where they received repeated
doses of 1 mg/kg of ketamine over 12 weeks, with the dose fre-
quency adjusted according to the duration of response to keta-
mine.35 Patients who responded to initial ketamine treatment
remained in remission with maintenance treatment over 3
months; however, the recurrence of symptoms was common
within 2 weeks of stopping treatment.35
A cross-over RCT of a single dose of ketamine (0.5 mg/kg) for
social anxiety disorder reported that ketamine led to significantly
greater number of responders compared with placebo, with six
out of 18 participants experiencing a reduction in clinician-rated
anxiety scores of at least 35%, compared with none of 17 partici-
pants who received placebo.90 Similarly, 16 out of 18 participants
who received ketamine experienced 50% or more reduction in
self-reported anxiety scores, compared with nine out of 17 in the
placebo group; this group difference was statistically significant.90
Obsessive–compulsive disorders
We identified two studies. First, in a cross-over RCT, patients
without depression and with chronic and treatment-resistant obses-
sive–compulsive disorder who received a single dose of intravenous
ketamine had lower obsessive–compulsive disorder scores than
those receiving placebo at 4 h and at 7 days following the infusion.91
Half of those receiving ketamine demonstrated a 35% or more
reduction in obsessive–compulsive disorder symptoms, compared
with none of the placebo group. An open-label trial of a single
dose of ketamine (0.5 mg/kg intravenous) in ten participants with
severe treatment refractory obsessive–compulsive disorder found
a significant but transient benefit in clinician-rated obsessive–com-
pulsive disorder symptoms at 1–3 h after infusion.92
Post-traumatic stress disorder
Eight publications that investigated the association between keta-
mine and post-traumatic stress disorder were identified. One
RCT93 and two open-label trials expressly focused on ketamine
treatment for post-traumatic stress disorder symptoms,94,95
whereas the other five retrospectively examined the effects of peri-
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traumatic anaesthetic ketamine administration during treatment for
physical injury.96–100
The first retrospective study found that patients who were admi-
nistered ketamine following trauma exposure demonstrated
increased post-traumatic stress disorder symptoms at 1 year,96 and
a subsequent study by the same group identified increased symptoms
of acute stress disorder, a precursor to post-traumatic stress disorder,
3 days subsequent to emergency treatment in people given ketamine
compared with opioid and other analgesics.97
Three studies examining post-traumatic stress disorder in USA
military personnel who had been administered ketamine for
service-related injuries reported conflicting results. In the first
study, receiving perioperative ketamine was associated with lower
post-traumatic stress disorder prevalence (27% compared with
46%) among those who had not received ketamine, despite
increased burn size, longer hospital stay and increased number of
operations in the ketamine group.98 Ketamine use during surgical
procedures also had a significant but weak negative correlation
with post-traumatic stress disorder.98 In contrast, two subsequent
studies reported comparable rates of post-traumatic stress disorder
and post-traumatic stress disorder symptoms among ketamine and
non-ketamine groups, although one of these studies was reported to
have low power (<%80).99,100
Three studies focused on ketamine for the treatment of post-
traumatic stress disorder. An open-label trial of six infusions (0.5
mg/kg) over 12 days in 15 military veterans with chronic post-trau-
matic stress disorder and depression reported a significant decrease
in post-traumatic stress disorder and depression symptoms 24 h
after the final infusion.94 At 14 days post-treatment, 80% of the
sample were in remission from post-traumatic stress disorder symp-
toms, and 40% remained in remission at the end of the 56-day
follow-up period.94 Similarly, in another open-label study, 30 parti-
cipants received six ketamine infusions beginning at 1 mg/kg; a sig-
nificant reduction (44%) in post-traumatic stress disorder
symptoms was observed from baseline to before the sixth infusion.95
A cross-over RCT of a single intravenous subanaesthetic dose of
ketamine (0.5 mg/kg) among 41 patients with chronic post-trau-
matic stress disorder reported that post-traumatic stress disorder
symptom severity was improved compared with midazolam at 24
h, but not at 7 days.93
Substance use disorders
We identified 14 studies examining ketamine as a treatment for sub-
stance use disorders, including six studies focusing on alcohol use
disorder,16,17,101–104 five on cocaine use disorder31,105–108 and
three on opiate use disorder.18,19,109
Alcohol use disorders
One study examined ketamine in combination with aversive
therapy approaches that aim to establish negative links between
alcohol consumption and alcohol’s detrimental effect.16 It was
reported that 70% of participants in the ketamine group remained
abstinent at 1 year compared with 24% of participants who received
aversion therapy alone.16 A subsequent study compared in-patients
who selected KAP versus conventional psychotherapy reported 12-
month abstinence rates of 66% for the ketamine group compared
with 24% of controls.17
More than 20 years later, an RCT of a single ketamine intraven-
ous infusion (0.71 mg/kg) paired with motivational enhancement
therapy for alcohol dependence reported that ketamine significantly
increased abstinence rates and led to a lower likelihood of alcohol
use and heavy drinking, and longer time to relapse over 21 days
after infusion, compared with midazolam.104 Of those available at
6-month follow-up, 75% in the ketamine group reported abstinence,
whereas only 27% did so in the midazolam group.104
Ketamine may also have a role in the detoxification stage of
treatment: three retrospective cohort studies of the safety and effi-
cacy of ketamine for the management of alcohol withdrawal syn-
drome concluded that ketamine was safe.101–103
Cocaine use disorders
Three studies by a single research group have investigated ketamine
administration on individuals with cocaine use disorders. An
experimental study in cocaine dependent volunteers reported that
a single dose of ketamine (0.41 mg/kg) increased motivation to
quit cocaine and reduced cue induced craving significantly more
than lorazepam at 24-h follow-up.106 The second dose (0.71 mg/
kg) further decreased cue-induced craving for an additional day
after administration.106 At 4 weeks, all participants reported a sig-
nificant reduction in amount and frequency of cocaine use.106
A second report on the same participants indicated that these
effects were mediated by ketamine-induced mystical experiences.105
In a subsequent experimental controlled study with community
follow-up, a single dose of ketamine infusion (0.71 mg/kg) signifi-
cantly reduced choices for cocaine self-administration versus
money, compared with midazolam, among 20 cocaine-dependent
individuals.107 The reduction of cocaine choices in the ketamine
group represented a 67% reduction from baseline.107
Furthermore, the ketamine group reported significant reductions
in cocaine use during the first 3 days of follow-up compared with
the midazolam group, which dissipated at 2 weeks.107 A subsequent
report from the same sample reported that mystical, but not
dissociative, acute effects mediated efficacy.31
A subsequent RCT from the same research group assigned
55 cocaine-dependent patients to either ketamine (0.5 mg/kg) or
midazolam (0.025 mg/kg) combined with mindfulness-based
relapse prevention therapy.108 At the end of the 14-day study
period, 48% of participants in the ketamine group (n = 27) remained
abstinent compared with 11% in the midazolam group (n = 28),
showing a large effect of ketamine.108 Craving scores were also
58% lower in the ketamine group, and at the 6-month follow-up,
44% of the ketamine group reported cocaine abstinence compared
with none of the midazolam group.108
Opioid use disorders
Two RCTs from the one research group examined the use of
ketamine-assisted psychotherapy for heroin use disorders.18,19
A trial that compared a higher dose of ketamine (2 mg/kg) to a
lower dose (0.2 mg/kg) among 70 detoxified heroin-dependent
individuals reported reduced craving in both groups, with a larger
effect from the higher dose.18 Craving stayed reduced in the
high-dose group at 24 months, but did not last beyond 1 month
in the low-dose group. The rate of abstinence was also higher in
the high-dose group at both intervals.18 A subsequent longitudinal
study that compared single versus three sessions of KAP among 53
heroin-dependent patients reported that participants who received
three sessions demonstrated a significantly higher abstinence rate
of 50% compared with 22% for those who received a single session.19
Ketamine may also assist in withdrawal from opiates. The lone
RCT in this area reported that ketamine infusion (0.5 mg/kg) was
associated with less additional medication required to manage
acute opiate withdrawal, but was unrelated to treatment outcome
at 4-month follow-up.109
Eating disorders
One open-label trial of ketamine infusion (20 mg/h for 10 h) among
in-patients with eating disorder diagnoses reported that nine out of
Walsh et al
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15 patients showed a marked and sustained return to normal eating
behaviour and acceptance of normal weight.110 Variability in
follow-up intervals and a somewhat idiosyncratic dosing regimen
complicate inferences regarding the duration and generalisability
of effects, although these results suggest that further investigation
of ketamine therapy for eating disorders is needed.
Adverse effects and risks
Two studies explicitly reported no adverse effects16,17 and 19 did not
formally report presence or absence of adverse effects.48,51,53,55,61–
66,76,84,88,95–100 The remaining studies all reported adverse effects,
with the most common being mild and transient increases in
blood pressure that returned to baseline levels within 30–120
min.40,72,83,87,102,106 Tachycardia and bradycardia were also
reported, particularly at higher doses of ketamine,6,86,89,90 and
more severe cardiac effects. including intermittent atrial fibrillation
and single salve of ventricular extrasystoles. Were observed in two
patients with pre-existing conditions who made a full recovery.70
Most studies also reported transient and dose-dependent dissocia-
tive and psychotomimetic effects, including unusual thought content,
visual hallucinations and conceptual disorganisation that peaked
during and immediately following ketamine infusion and rapidly
resolved within up to 2 h after infusion.9,14,34,40,50,52,54,58,60,72,85,87,89,90
Across the whole review, in two separate studies, one out of 41 and
31 patients, respectively, discontinued study participation because of
dissociative or hallucinatory effects.71,93
Dysphoria and treatment-emergent suicidal ideationwere reported
in one study.92 Additionally, there were some reports of transient
mania and hypomania that resolved by 80 min following infusion14
among patients with bipolar disorder who underwent ketamine infu-
sion with74 or without ECT,14,58 although treatment-emergent mania
was not observed more frequently in the ketamine group compared
with the placebo.58 Transient increases in anxiety during ketamine
infusions are also frequently reported, with symptoms typically declin-
ing within 80–120 min,3,14,90 although the review also included two
cases of anxiety persisting up to 1–2 days after infusion.92
Non-dissociative effects associated with ketamine administra-
tion included mild sedation, agitation, nausea and vomiting, head-
aches, dizziness, blurred vision, dry or numb mouth, delirium,
irritability, sensory changes, urination problems, vertigo and drow-
siness; these were overwhelmingly reported to dissipate within 1–2
h of ketamine infusion.3,6,12,14,15,35,40,41,43,47,52,58,69–72,78,82,83,85,87,89–
91,93,101,103,104,108,110
We found no reports of ketamine use/misuse following treat-
ment with ketamine, nor is there evidence of transition from
medical to non-medical ketamine use.12,54
Risk of bias
The results of the risk-of-bias analysis is reported in Supplementary
Appendix 1 for randomised studies, Supplementary Appendix 2 for
non-randomised studies and Supplementary Appendix 3 for sys-
tematic reviews/meta-analyses. Most randomised trials were
judged to be at either high risk of bias or raise some concerns in
at least one domain. Most common areas of concern were selection
of the reported results, randomisation and allocation concealment,
deviations from intended interventions, missing data and measure-
ment of outcome. Most non-randomised studies were also judged to
be at serious risk of bias. All non-randomised studies suffered from
risk of bias because of a lack of control and measurement for base-
line confounding, and all except one was judged to be at serious risk
of bias because of the measurement of outcome. Other areas of
concern included retrospective classification of outcomes, selection
bias, deviations from intended interventions and missing outcome
data. According to the AMSTAR Checklist, the majority of the
systematic reviews were of critically low quality. Frequent critical
issues were lack of reference to a registered review protocol, and
lack of risk-of-bias analysis and consideration of risk of bias in
the interpretation of findings.
Discussion
Interest in ketamine therapies for mental health concerns expanded
dramatically between 2010 and 2020 (Fig. 2). Recent FDA and
European Medicines Agency approvals for esketamine in treat-
ment-resistant depression and the broader re-emergence of psyche-
delic medicines prognosticate accelerating use and demand for
ketamine in mental health treatment over the coming decade. The
current review focused on the areas we feel are most central to clin-
ical practice: affective disorders, suicidal ideation, anxiety disorders,
post-traumatic stress disorder, obsessive–compulsive disorder, sub-
stance use disorders and eating disorders.
Affective disorders and suicidal ideation are the category of psy-
chopathology with the most robust evidence regarding ketamine
therapies, based on multiple systematic reviews and meta-analyses.
Although there was some evidence to support effectiveness of keta-
mine administration for other indications (post-traumatic stress
disorder, obsessive–compulsive disorder, anxiety and substance
use disorders), the evidence base comprised a small number of
mostly non-randomised trials with often short follow-up periods,
therefore requiring corroboration and extension. The challenges
to interpretation presented by this paucity of evidence are exacer-
bated by cross-study variations in dose, modes of administration
and adjunctive therapies, the combination of which complicates
the determination of what works for whom. Research to optimise
adjunctive psychotherapy and the broader ‘set and setting’ of keta-
mine experiences are also required to estimate the parameters of
ketamine effects in the context of psychological health.
Nonetheless, extant evidence provides signals that permit some pro-
visional observations.
Across all studies where treatment effects have been consistently
observed, there is a need to profile treatment responders, along with
identifying dose and route of administration and other factors that
may prolong the effectiveness of ketamine therapy. Additionally,
further research with comparisons to active placebos is required
to evaluate comparative efficacy. Attempts to calculate the compara-
tive efficacy of different administration routes are encumbered by
the heterogeneity across studies, particularly with regards to fre-
quency of administration: studies examining intranasal ketamine
involve repeated doses, whereas most studies on intravenous keta-
mine consist of a single infusion.55 Research that explores means
of extending effect duration is also required to identify best practices
for ketamine in the context of psychiatric disorders. In addition to
specifying optimal duration and frequency of dose, determining
the extent to which clinical preparation, integration and guidance
during the acute experience extends the duration and power of
therapeutic effects is a research priority, as is the further elucidation
of the importance of subjective effects such as mystical experiences.
From a more practical standpoint, evaluating modes of admin-
istration such as intramuscular and intranasal, which are less inva-
sive and demanding of clinical resources, may be important for
reducing barriers to access. The burden of affective disorders is
borne disproportionately by those at lower levels of socioeconomic
status,111 and as such, research should also focus onmeans of ensur-
ing accessibility and equity in the delivery of ketamine therapies,
including testing racemic ketamine against enantiomers. Finally,
extant research does not speak conclusively to the safety of repeated
administration over time, and as such, longitudinal research on
Ketamine treatment for mental and health substance use disorders
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safety is essential for informed estimation of risks and benefits of
ketamine relative to other therapeutic options.
The combined anaesthetic and antidepressant effects of keta-
mine make it an appealing adjunct during ECT for depression,
and our review suggests that the addition of ketamine to ECT can
lead to longer seizure duration, fewer required treatment sessions,
accelerate symptom reduction and time to remission. The thera-
peutic effects of ketamine with ECT have been most comprehen-
sively demonstrated for treatment-resistant depression,70,71,82 with
less robust adjunctive effects in MDD and bipolar disorder, high-
lighting the need for further research to clarify when and for
whom ketamine might accentuate the benefits of ECT.
Given that ketamine may also be used recreationally, it is
notable that even in addiction treatment, no studies in our review
report a transition to illicit use engendered by introduction to keta-
mine in a therapeutic context. Future research should continue to
monitor this potential adverse effect of ketamine therapy in the
context of substance use disorders. However, given the negative
consequences of substance use disorders, particularly the grave
harm of overdose associated with opioid misuse, the relatively
modest risks of ketamine misuse should not present a barrier to
treatment for opioid use disorders or for psychiatric comorbidities
that may accompany opioid misuse. Conversely, patients who use
ketamine outside of medical supervision should be queried to deter-
mine the extent to which this use might reflect therapeutic motives
as a drug substitute or to address negative affect.
Several areas warrant further research. In particular, the import-
ance of subjective experience and adjunctive psychotherapy in rela-
tion to the effects of ketamine are key areas where the extant
literature is limited by the lack of more rigorous randomised
control designs, which have been effective in bolstering the evidence
for other forms of psychedelic-assisted psychotherapy such as
MDMA-assisted psychotherapy112 and psilocybin-assisted psycho-
therapy.113 Further research should also attempt to elucidate the
mechanisms by which ketamine effects such a broad range of
mental health conditions. The apparent diversity of ketamine thera-
peutic action has led to speculation regarding potential cross-
cutting mechanisms, including the proposal that ketamine may
affect the higher-order personality trait of neuroticism,114 enhance
mindfulness and provide therapeutic experiences of self-acceptance
and absence of negative emotions,12 but these interesting proposals
have not been subject to rigorous tests.
There is also surprising paucity of research on ketamine treatment
for personality disorders and eating disorders. We identified no
reports on personality disorders and one small open-label trial for
eating disorders. In light of recent interest in the use of psychedelic-
assisted psychotherapy for eating disorders and the limited treatment
options for eating disorders, further examination of the therapeutic
potential of ketamine for eating disorders is warranted.115–118 With
regard to personality disorders, the high levels suicidality associated
with borderline personalitymakes research on ketamine for suicidality
also a priority among this population. Moreover, in light of the posi-
tive effects of ketamine for depressive disorders, the lack of research on
the use of ketamine in the treatment of postpartum depression is a
notable gap that demands consideration.
The most common adverse effects associated with ketamine
administration were increases in systolic and diastolic blood pres-
sure, dissociation and psychotomimetic symptoms, all of which
were short lived. However, given the relatively nascent state of
research and practice in the area of ketamine for mental health,
further research is required to definitively determine the safety
and tolerability of ketamine in psychiatric populations, particularly
over the longer term. Nonetheless, extant evidence on the risks of
ketamine suggest a profile that is comparable to other widely used
psychiatric medications.
The current review provides a comprehensive overview of the
evidence base for ketamine treatment across psychiatric disorders,
including depression, bipolar disorder, anxiety disorders, post-trau-
matic stress disorders, obsessive–compulsive disorders, substance
use disorders and eating disorders. We used an extensive search
strategy covering a number of databases and trial registries to iden-
tify all relevant literature. Nonetheless, there are a number of limita-
tions to consider. First, because of the high number of studies
included in the review, single review authors undertook data extrac-
tion and rated risk of bias; however, all reviewers were trained in
using the forms, and a selection of data extraction and risk of bias
forms were piloted for accuracy and completeness. It is also worth
noting that majority of the studies included in the review were
rated as at high risk of bias because of a number of methodological
limitations outlined in the risk of bias results, so the results should
be interpreted with caution. Moreover, although evidence from
MDD suggests that ketamine effects and risks are consistent
across use of concomitant medications, further research is required




















































































Fig. 2 Number of publications with search terms ketamine and mental health in PubMed per year, from 1975 till December 2020.
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generalise to other conditions and across diverse classes of medica-
tions. In particular, it may be interesting to examine the extent to
which ketamine effects interact with those of other interventions
emerging under the banner of psychedelic-assisted psychotherapy.
Additionally, included studies were heterogenous in terms of keta-
mine administration (dose, number, route of delivery), measure-
ment of outcomes, length of follow-up, study design and setting,
which reduces comparability.
There are a number of methodological differences between keta-
mine studies that would benefit from standardising to aid interpret-
ation of findings as more psychiatric indications are researched as
targets for ketamine treatment. One area of discrepancy has been
the use of active (typically midazolam) versus inactive placebos
(typically saline). Although earlier studies in depression used
inactive placebos, active placebos have begun to be adopted.
Benefits of active placebos are in providing more confidence in
blinding to treatment allocation, where the subjective effects of
the drug make blinding difficult, as with ketamine. Concerns
about active placebos are that they may have unintended treatment
consequences; for example, in studies for anxiety, where benzodia-
zepines are used as a treatment. However, in the studies reviewed
here, this is not consistently observed; for instance, in the study
by Dakwar et al,104 more individuals dropped out from the midazo-
lam group and returned to heavy drinking compared with the keta-
mine group. Among those with anxiety disorders, midazolam had
small transient effects on anxiety symptoms, equivalent to 0.25
mg/kg ketamine,89 suggesting that using midazolam as active
control at higher doses of ketamine (e.g. 0.5 mg/kg) should not
obscure the active treatment effect. In addition to using active pla-
cebos, some researchers have attempted to minimise expectancy
effects by informing the participants that they may receive any
one of a number of psychoactive drugs, including ketamine.104,105
Future trials of ketamine or other drugs with identifiable psycho-
active effects can also minimise bias by having independent
outcome assessors who are not present during drug administration.
Similar differences have been in the use of cross-over studies
(within participants) or between-participant designs. The merit of
the former is the ability to observe effects in the same participants,
thus negating the issue of pre-existing group difference, but it can be
confounded by persisting treatment and order effects. Similarly,
with studies where participants all take part in both arms, this can
compound blinding issues even where participants are given
active placebos. Upon reviewing the literature, we would recom-
mend the use of active placebos where possible, in between-partici-
pant designs.
Numerous avenues are ripe for exploration in future treatment
approaches with ketamine. One area of interest is in creating trials to
tackle the problem of comorbidities and multi-morbidities, which
are often more representative of the psychiatric population at
large, where ‘pure’ diagnoses are rare. Ketamine seems a good solu-
tion to the problem of multi-morbidities as it is emerging as an
effective treatment for a number of conditions, and this raises the
issue of whether strict diagnostic criteria that have been used in
the past should be considered for entry into clinical trials, or
whether expanding to treat presenting symptoms with a formula-
tion-based approach may be more appropriate.
Trials have also only begun to investigate the synergies between
ketamine and psychological therapy, and future research should
design full factorial approaches to assess both the additive and inter-
active effects of combining such interventions. Based on the extant
literature, it is difficult to prescribe even a minimum adequate
behavioural framework for giving ketamine clinically, but research
from clinical use of KAP12 and qualitative studies in the field119
suggest that sufficient preparation before the experience, a clinical
and professional setting and trusting and supportive relationships
with staff is crucial, as patients are very sensitive to minor disrup-
tions in the setting. Given findings that ketamine’s therapeutic ben-
efits can be extended with psychological therapy,29,120 it is advisable
to provide ketamine treatment alongside a psychological therapy.
Certain psychological therapies may be particularly compatible
with ketamine treatment. For instance, combining ketamine
with motivational enhancement therapy may further increase
motivation to remain abstinent in alcohol and substance use disor-
ders, because of ketamine’s effect on increasing motivation to quit
drug use.106 Alternatively, because of ketamine’s mystical and spir-
itual effects, it may serve to deepen the mindfulness practice culti-
vated by mindfulness-based therapies. However, choice of
adjunctive therapy should also be informed by the symptoms of
the patient population.
Another important consideration in trial design is representa-
tiveness of the trial population and access to these trials, and later
therapies by individuals from disadvantaged groups. Inequalities
in access to healthcare are replicated in access to clinical trials,
with some exceptions.106–108 Trials fail to consistently report on eth-
nicity and socioeconomic status, which are important to gauge the
generalisability of the findings to the population at large, and should
be considered a minimum standard of clinical trial reporting.
Recent efforts in this research space to create culturally informed
research designs (e.g. Williams et al121) should be translated to keta-
mine research and are important examples of ways to diversify
research in this field, an area that has been hitherto neglected and
is urgently needed.122
In conclusion, the plethora of evidence from the systematic
reviews and meta-analyses reviewed here supports a robust, rapid
and transient antidepressant effect of ketamine in unipolar and
bipolar depression, as well as treatment-resistant depression, with
repeated dosing increasing the duration of effectiveness. In numer-
ous studies, ketamine was also demonstrated to have short-lived
anti-suicidal properties, independently of improvements in depres-
sive symptoms. A small number of trials provide some evidence to
support the beneficial effects of ketamine for post-traumatic stress
disorder and obsessive–compulsive disorder. Ketamine’s anxiolytic
effects for social anxiety disorder and generalised anxiety disorder
have also been reported, nonetheless symptom recurrence follow-
ing treatment was common. There is also evidence that ketamine
results in short-term increases in abstinence, reductions in use,
cravings and symptoms of withdrawal related to problematic sub-
stance use. In light of the substantial mortality associated with
opioid overdose, the potential of ketamine to address opioid use
disorders is particularly encouraging and worthy of further
investigation.
Notably, the majority of the research we reviewed was classi-
fied as being at high risk of bias, as most studies are small and
have other methodological limitations. There is also much still
to determine regarding synergistic effects with psychological
therapy and to better specify therapeutic modalities. Research on
optimal dose, route and frequency of administration that fore-
grounds accessibility and equity will also be paramount to
reduce barriers to access among the lower income and margina-
lised communities that are disproportionately affected by the con-
ditions for which this promising treatment may be effective.
In sum, despite important unknowns regarding means of
prolonging effects and risk over time associated with long-term
repeated use, interest in the psychiatric applications of ketamine
has accelerated dramatically over the past decade. This interested
is warranted given ketamine’s broad spectrum of potential
applications in psychiatric treatment, with limited adverse
effects. In light of recent progress in the development and
application of ketamine-based psychiatric medicines, as well as
broader developments in psychedelic-assisted psychotherapy, it
Ketamine treatment for mental and health substance use disorders
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seems almost certain that interest and uptake of psychiatric use of
ketamine will expand even further in the decades to come.
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et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of
interventions. BMJ 2016; 355: i4919.
39 Shea B, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a
critical appraisal tool for systematic reviews that include randomised or
non-randomised studies of healthcare interventions, or both. BMJ 2017;
358: j4008.
40 Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype
glutamatergic antidepressant: pharmacodynamic actions, and a systematic
review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014; 4(2):
75–99.
41 Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, et al.
Ketamine and other glutamate receptor modulators for depression in adults.
Cochrane Database Syst Rev 2015; 9: CD011612.
42 Covvey J, Crawford AN, Lowe DK. Intravenous ketamine for treatment-resist-
ant major depressive disorder. Ann Pharmacother 2012; 46(1): 117–23.
43 Coyle C, Laws KR. The use of ketamine as an antidepressant: a systematic
review and meta-analysis. Hum Psychopharmacol 2015; 30(3): 152–63.
44 Garay R, Zarate CA Jr, Charpeaud T, Citrome L, Correll CU, Hameg A, et al.
Investigational drugs in recent clinical trials for treatment-resistant depres-
sion. Expert Rev Neurother 2017; 17(6): 593–609.
45 Han Y, Chen J, Zou D, Zheng P, Li Q, Wang H, et al. Efficacy of ketamine in the
rapid treatment of major depressive disorder: a meta-analysis of randomized,
double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat 2016; 12:
2859–67.
46 Jankauskas V, Necyk C, Chue J, Chue P. A review of ketamine’s role in ECT and
non-ECT settings. Neuropsychiatr Dis Treat 2018; 14: 1437–50.
47 Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, et al. Single-
dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor
antagonists for unipolar and bipolar depression: a meta-analysis of efficacy,
safety and time trajectories. Psychol Med 2016; 46(7): 1459–72.
48 Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S. Efficacy of off-label aug-
mentation in unipolar depression: a systematic review of the evidence. Eur
Neuropsychopharmacol 2017; 27(5): 423–41.
49 Kolar D. Addictive potential of novel treatments for refractory depression and
anxiety. Neuropsychiatr Dis Treat 2018; 14: 1513–9.
50 McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic
review and meta-analysis of randomized, double-blind, placebo-controlled
trials of ketamine in the rapid treatment of major depressive episodes.
Psychol Med 2014; 45(4): 693–704.
51 Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative
efficacy and tolerability of pharmacological and somatic interventions in adult
patients with treatment-resistant depression: a systematic review and net-
work meta-analysis. Curr Med Res Opin 2017; 33(4): 701–11.
52 Zheng W, Cai DB, Xiang YQ, Zheng W, Jiang WL, Sim K, et al. Adjunctive intra-
nasal esketamine for major depressive disorder: a systematic review of ran-
domized double-blind controlled-placebo studies. J Affect Disord 2020; 265:
63–70.
53 Papakostas G, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, et al.
Efficacy of esketamine augmentation in major depressive disorder: a meta-
analysis. J Clin Psychiatry 2020; 81(4): 19r12889.
54 Rosenblat J, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral
ketamine for depression: a systematic review. J Clin Psychiatry 2019; 80(3):
18r12475.
55 McIntyre R, Carvalho IP, Lui L, Majeed A, Masand PS, Gill H, et al. The effect of
intravenous, intranasal, and oral ketamine in mood disorders: a meta-ana-
lysis. J Affect Disord 2020; 276: 576–84.
56 Alberich S, Martínez-Cengotitabengoa M, López P, Zorrilla I, Núñez N, Vieta E,
et al. Efficacy and safety of ketamine in bipolar depression: a systematic
review. Rev Psiquiatr Salud Ment 2017; 10(2): 104–12.
57 McCloud T, Caddy C, Jochim J, Rendell J, Diamond P, Shuttleworth C, et al.
Ketamine and other glutamate receptor modulators for depression in bipolar
disorder in adults. Cochrane Database Syst Rev 2015; 9: CD011611.
58 FornaroM, Carvalho AF, Fusco A, Anastasia A, SolmiM, BerkM, et al. The con-
cept and management of acute episodes of treatment-resistant bipolar dis-
order: a systematic review and exploratory meta-analysis of randomized
controlled trials. J Affect Disord 2020; 276: 970–83.
59 Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S,
et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in
treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67(8):
793–802.
60 Zarate C Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N,
Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar
depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71(11):
939–46.
61 Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal idea-
tion: a systematic review of the literature. Drugs R D 2015; 15(1): 37–43.
62 Bartoli F, Riboldi I, Crocamo C, Di Brita C, Clerici M, Carrà G. Ketamine as a
rapid-acting agent for suicidal ideation: a meta-analysis. Neurosci Biobehav
Rev 2017; 77: 232–6.
63 Wilkinson S, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al.
The effect of a single dose of intravenous ketamine on suicidal ideation: a sys-
tematic review and individual participant data meta-analysis. Am J Psychiatry
2018; 175(2): 150–8.
64 D’Anci K, Uhl S, Giradi G, Martin C. Treatments for the prevention andmanage-
ment of suicide: a systematic review. Ann Intern Med 2019; 171(5): 334–42.
65 Dadiomov D, Lee K. The effects of ketamine on suicidality across various for-
mulations and study settings. Ment Health Clin 2019; 9(1): 48–60.
66 Witt K, Potts J, Hubers A, GrunebaumMF,Murrough JW, Loo C, et al. Ketamine
for suicidal ideation in adults with psychiatric disorders: a systematic review
andmeta-analysis of treatment trials.Aust N Z J Psychiatry 2020; 54(1): 29–45.
67 Gálvez V, Li A, Huggins C, Glue P, Martin D, Somogyi AA, et al. Repeated intra-
nasal ketamine for treatment-resistant depression–theway to go? Results from
a pilot randomised controlled trial. J Psychopharmacol 2018; 32(4): 397–407.
68 Kellner C, Iosifescu DV. Ketamine and ECT: better alone than together? Lancet
Psychiatry 2017; 4(5): 348–9.
69 Gamble JJ, Bi H, Bowen R, Weisgerber G, Sanjanwala R, Prasad R, et al.
Ketamine-based anesthesia improves electroconvulsive therapy outcomes:
a randomized-controlled study. Can J Anaesth 2018; 65(6): 636–46.
70 Kranaster L, Kammerer-Ciernioch J, Hoyer C, Sartorius A. Clinically favourable
effects of ketamine as an anaesthetic for electroconvulsive therapy: a retro-
spective study. Eur Arch Psychiatry Clin Neurosci 2011; 261(8): 575–82.
71 Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T. Rapid
antidepressant effect of ketamine anesthesia during electroconvulsive ther-
apy of treatment-resistant depression: comparing ketamine and propofol
anesthesia. J ECT 2010; 26(3): 223–7.
72 Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C. Effects of propofol and keta-
mine as combined anesthesia for electroconvulsive therapy in patients with
depressive disorder. J ECT 2012; 28(2): 128–32.
73 Anderson IM, Blamire A, Branton T, Brigadoi S, Clark R, Downey D, et al.
Ketamine augmentation of electroconvulsive therapy to improve neuro-
psychological and clinical outcomes in depression (Ketamine-ECT): a multi-
centre, double-blind, randomised, parallel-group, superiority trial. Lancet
Psychiatry 2017; 4(5): 365–77.
74 Loo CK, Katalinic N, Garfield JB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R.
Neuropsychological and mood effects of ketamine in electroconvulsive ther-
apy: a randomised controlled trial. J Affect Disord 2012; 142(1–3): 233–40.
75 Shams-Alizadeh N, Maroufi A, Nasseri K, Najafabadi SHS, Taghiabad AM,
Gharibi F, et al. Antidepressant effect of combined ketamine and electrocon-
vulsive therapy on patients with major depressive disorder: a randomized
trial. Iran J Psychiatry Behav Sci 2015; 9(3): e1578.
76 Rybakowski JK, Bodnar A, KrzywotulskiM, Chlopocka-WozniakM,MichalakM,
Rosada-Kurasinska J, et al. Ketamine anesthesia, efficacy of electroconvulsive
therapy, and cognitive functions in treatment-resistant depression. J ECT
2016; 32(3): 164–8.
77 Yoosefi A, Sepehri AS, Kargar M, Akhondzadeh S, Sadeghi M, Rafei A, et al.
Comparing effects of ketamine and thiopental administration during electro-
convulsive therapy in patients with major depressive disorder: a randomized,
double-blind study. J ECT 2014; 30(1): 15–21.
78 Zhong X, He H, Zhang C, Wang Z, Jiang M, Li Q, et al. Mood and neuropsycho-
logical effects of different doses of ketamine in electroconvulsive therapy for
treatment-resistant depression. J Affect Disord 2016; 201: 124–30.
Ketamine treatment for mental and health substance use disorders
11
Downloaded from https://www.cambridge.org/core. 23 Dec 2021 at 15:47:41, subject to the Cambridge Core terms of use.
79 Carspecken CW, Borisovskaya A, Lan S-T, Heller K, Buchholz J, Ruskin D, et al.
Ketamine anesthesia does not improve depression scores in electroconvul-
sive therapy: a randomized clinical trial. J Neurosurg Anesthesiol 2018; 30
(4): 305–13.
80 Fernie G, Currie J, Perrin JS, Stewart CA, Anderson V, Bennett DM, et al.
Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT ran-
domised controlled trial. Br J Psychiatry 2017; 210(6): 422–8.
81 Rasmussen KG, Kung S, LapidMI, Oesterle TS, Geske JR, Nuttall GA, et al. A ran-
domized comparison of ketamine versus methohexital anesthesia in electro-
convulsive therapy. Psychiatry Res 2014; 215(2): 362–5.
82 Salehi B, Mohammadbeigi A, Kamali A, Taheri-NejadM,Moshiri I. Impact com-
parison of ketamine and sodium thiopental on anesthesia during electrocon-
vulsive therapy in major depression patients with drug-resistant; a double-
blind randomized clinical trial. Ann Card Anaesth 2015; 18(4): 486–90.
83 Zhang M, Rosenheck R, Lin X, Li Q, Zhou Y, Xiao Y, et al. A randomized clinical
trial of adjunctive ketamine anaesthesia in electro-convulsive therapy for
depression. J Affect Disord 2018; 227: 372–8.
84 Altinay M, Karne H, Anand A. Administration of sub-anesthetic dose of keta-
mine and electroconvulsive treatment on alternate week days in patients
with treatment resistant depression: a double blind placebo controlled trial.
Psychopharmacol Bull 2019; 49(1): 8–16.
85 Dong J, Min S, Qiu H, Chen Q, Ren L. Intermittent administration of low dose
ketamine can shorten the course of electroconvulsive therapy for depression
and reduce complications: a randomized controlled trial. Psychiatry Res 2019;
281: 112573.
86 Ray-Griffith S, Eads LA, Han X, Golden K, Stowe ZN. A randomized pilot study
comparing ketamine and methohexital anesthesia for electroconvulsive ther-
apy in patients with depression. J ECT 2017; 33(4): 268–71.
87 Finnegan M, Galligan T, Ryan K, Shanahan E, Harkin A, Daly L, et al. Ketamine
versus midazolam for depression relapse prevention following successful
electroconvulsive therapy: a randomized controlled pilot trial. J ECT 2019;
35(2): 115–21.
88 Shadli S, Kawe T, Martin D, McNaughton N, Neehoff S, Glue P. Ketamine
effects on EEG during therapy of treatment-resistant generalized anxiety
and social anxiety. Int J Neuropsychopharmacol 2018; 21(8): 717–24.
89 Glue P, Neehoff S, Sabadel A, Broughton L, Le Nedelec M, Shadli S, et al.
Effects of ketamine in patients with treatment-refractory generalized anxiety
and social anxiety disorders: exploratory double-blind psychoactive-con-
trolled replication study. J Psychopharmacol 2019; 34(3): 267–72.
90 Taylor J, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA,
Gabriel D, et al. Ketamine for social anxiety disorder: a randomized, pla-
cebo-controlled crossover trial. Neuropsychopharmacology 2018; 43(2):
325–33.
91 Rodriguez C, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, et al.
Randomized controlled crossover trial of ketamine in obsessive-compulsive
disorder: proof-of-concept. Neuropsychopharmacology 2013; 38(12): 2475–83.
92 Bloch M, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E,
Leckman JF, et al. Effects of ketamine in treatment-refractory obsessive-com-
pulsive disorder. Biol Psychiatry 2012; 72(11): 964–70.
93 Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, et al.
Efficacy of intravenous ketamine for treatment of chronic posttraumatic
stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71(6):
681–8.
94 Albott C, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, et al. Efficacy,
safety, and durability of repeated ketamine infusions for comorbid post-
traumatic stress disorder and treatment-resistant depression. J Clin
Psychiatry2018; 79(3): 17m11634.
95 Ross C, Jain R, Bonnett CJ, Wolfson P. High-dose ketamine infusion for the
treatment of posttraumatic stress disorder in combat veterans. Ann Clin
Psychiatry 2019; 31(4): 271–9.
96 Schönenberg M, Reichwald U, Domes G, Badke A, Hautzinger M. Effects of
peritraumatic ketamine medication on early and sustained posttraumatic
stress symptoms in moderately injured accident victims. Psychopharmacol
Bull 2005; 182(3): 420–5.
97 Schönenberg M, Reichwald U, Domes G, Badke A, Hautzinger M. Ketamine
aggravates symptoms of acute stress disorder in a naturalistic sample of acci-
dent victims. J Psychopharmacol 2008; 22(5): 493–7.
98 McGhee L, Maani CV, Garza TH, Gaylord KM, Black IH. The correlation between
ketamine and posttraumatic stress disorder in burned service members.
J Trauma Acute Care Surg 2008; 64(2): 195–9.
99 McGhee L, Maani CV, Garza TH, Slater TM, Petz LN, Fowler M. The intraopera-
tive administration of ketamine to burned US service members does not
increase the incidence of post-traumatic stress disorder. Mil Med 2014; 179
(suppl 8): 41–6.
100 Highland K, Soumoff AA, Spinks EA, Kemezis PA, Buckenmaier CC. Ketamine
administration during hospitalization is not associated with posttraumatic
stress disorder outcomes in military combat casualties: a matched cohort
study. Anesth Analg 2020; 13(2): 402–8.
101 Wong A, Benedict NJ, Armahizer MJ, Kane-Gill SL. Evaluation of adjunctive
ketamine to benzodiazepines for management of alcohol withdrawal syn-
drome. Ann Pharmacother 2015; 49(1): 14–9.
102 Shah P, McDowell M, Ebisu R, Hanif T, Toerne T. Adjunctive use of ketamine for
benzodiazepine-resistant severe alcohol withdrawal: a retrospective evalu-
ation. J Med Toxicol 2018; 14(3): 229–36.
103 Pizon A, Lynch MJ, Benedict NJ, Yanta JH, Frisch A, Menke NB, et al. Adjunct
ketamine use in the management of severe ethanol withdrawal. Crit Care
Med 2018; 46(8): 768–71.
104 Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, PavlicovaM, et al. A single keta-
mine infusion combined with motivational enhancement therapy for alcohol
use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry
2020; 177(2): 125–33.
105 Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic
infusions of ketamine: do the psychoactive effects matter? Drug Alcohol
Depend 2014; 136: 153–7.
106 Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic
ketamine infusions on motivation to quit and cue-induced craving in cocaine-
dependent research volunteers. Biol Psychiatry 2014; 76(1): 40–6.
107 Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW. Cocaine self-administration
disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a ran-
domized, crossover trial. Mol Psychiatry 2017; 22(1): 76–81.
108 Dakwar E, Nunes EV, Hart CL, Foltin RW,Mathew SJ, Carpenter KM, et al. A sin-
gle ketamine infusion combinedwithmindfulness-based behavioral modifica-
tion to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry
2019; 176(11): 923–30.
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